ストックスクリーナーアプリを入手
2.89
0.00%
0.00
アフターアワーズ：
2.79
-0.10
-3.46%
Soligenix Inc (SNGX) 最新ニュース
Soligenix, and Graphex Group Interviews to Air on Bloomberg TV on the RedChip Money Report(R) - StockTitan
Soligenix Advances Treatment for Rare Skin Cancer with HyBryte - Citybuzz
Soligenix begins enrolling subjects in cutaneous T-cell lymphoma treatment trial - Yahoo Finance
Soligenix Reports It Is On Cusp Of Treating Rare Cancer CTCL - Nasdaq
Soligenix initiates confirmatory Phase 3 trial of HyBryte - Yahoo Finance
SNGX: Phase 3 FLASH2 Trial of HyBryte in CTCL Underway - Smartkarma
SNGX: Phase 3 FLASH2 Trial of HyBryte in CTCL Underway… - Zacks Small Cap Research
EXCLUSIVE: Soligenix Starts Confirmatory Late-Stage Trial For HyBryte For Type Of Blood Cancer - AOL
Soligenix, Inc. Initiates Confirmatory Phase 3 Clinical Trial of HyBryte for the Treatment of Cutaneous T-Cell Lymphoma - Marketscreener.com
Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma - PR Newswire
Oral Mucositis Market expected to rise | Companies- Galera Therapeutics, Soligenix, Izun Pharma, MitoImmune Therapeutics, Tosk, Cellix Bio, Enzychem Lifesciences, Monopar Therapeutics - The Globe and Mail
Soligenix's HyBryte™ Shows 3x Better Response Rate vs Valchlor® in Rare Disease Trial - StockTitan
HyBryte™ Clinical Results Demonstrate Continued Improvement Post-Treatment - The Malaysian Reserve
Soligenix (STU:DOA) 3-Year Revenue Growth Rate : 0.00% (As of Sep. 2024) - GuruFocus.com
Soligenix, A Pharmaceutical Firm Tackling Potentially Lucrative Unmet Medical Needs - Nasdaq
Soligenix Advances Promising Treatments for Rare Diseases and Public Health Threats - Citybuzz
Soligenix Announces Recent Accomplishments And Third Quarter 202 - GuruFocus.com
Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusqueti - GuruFocus.com
Soligenix Launches European Advisory Board for Phase 3 HyBryte CTCL Trial - Dermatology Times
Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma - PR Newswire
Soligenix Trumpets Q2 Numbers - MENAFN.COM
Soligenix to Present at Q4 Investor Summit: Rare Disease Treatment Pipeline in Focus | SNGX Stock News - StockTitan
Brokers Offer Predictions for Soligenix FY2024 Earnings - Defense World
Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet's Disease - The Malaysian Reserve
Soligenix Kickstarts Dusquetide Mid-Stage Study For Patients With Inflamed Blood Vessels - AOL
Soligenix Initiates A Phase 2 Clinical Trial of SGX945 for the Treatment of Behcet's Disease - Marketscreener.com
SNGX: Phase 3 CTCL Trial to Initiate Before End of 2024 - MSN
Soligenix Third Quarter 2024 Earnings: US$0.78 loss per share (vs US$2.56 loss in 3Q 2023) - Yahoo Finance
Soligenix Inc. (SNGX) Quarterly 10-Q Report - Quartz
SEC Form 424B3 filed by Soligenix Inc. - Quantisnow
Soligenix Announces Recent Accomplishments And Third Quarter 2024 Financial Results - citybiz
Soligenix Reports Q3 Loss, Advances Clinical Pipeline with $9.8M Cash Position | SNGX Stock News - StockTitan
Soligenix Granted FDA Orphan Drug Designation For SuVax Active Ingredient - Contract Pharma
Oral Mucositis Market Forecasted to Surge in Coming Years, - openPR
Soligenix, Inc. to Present at the 2024 ThinkEquity Conference - GlobeNewswire
Soligenix gains Hong Kong patent for synthetic hypericin - Investing.com India
Soligenix to Present at Upcoming Conferences - GuruFocus.com
Soligenix gains Hong Kong patent for synthetic hypericin By Investing.com - Investing.com Nigeria
Oral Mucositis Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Swedish Orphan Biovitrum, Galera Therapeutics, EpicentRx, Galera Therapeutics, Inc., Soligenix - Barchart
Soligenix Receives Hong Kong Patent for Improved Production of Synthetic Hypericin - Lelezard
Soligenix Invited to Present at Upcoming Investor Conferences - StockTitan
Soligenix secures amended loan terms with Pontifax Medison - Investing.com India
Soligenix secures amended loan terms with Pontifax Medison By Investing.com - Investing.com UK
HyBryte™ Expanded Treatment Results to be Presented at the European Organisation for Research and Treatment of Cancer Conference - PR Newswire
2.14%
5.55%
大文字化:
|
ボリューム (24 時間):